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KESAN KALIUM KOETJAPAT, SATU TERBITAN ASID 
KOETJAPIK YANG DIASINGKAN DARIPADA SANDORICUM 
KOETJAPE MERR. KE ATAS KANSER KOLOREKTAL MANUSIA. 
 
ABSTRAK 
Dalam kajian ini, usaha dilakukan untuk menambahbaik pelarutan 
air acid koetjapik (KA) dan mengkaji efikasi anti - kanser kolonnya, 
menggunakan metod-metod ‘in vitro’ dan ‘in vivo’. Garam kalium KA 
iaitu, kalium koetjapat disediakan melalui metod separa -sintetik. Aktiviti-
aktiviti antikanser kalium koetjapat dibandingkan dengan aktiviti sebatian 
asal iaitu, KA. Asai viabiliti sel MTT digunakan untuk mendapatkan dan 
membandingkan nilai IC50 kedua-dua sebatian. Kesan-kesan pro-apoptotik 
kalium koetjapat dinilaikan dengan menggunakan asai kaspas -kaspas (3/7, 
8 dan 9), pewarna fluresen Hoechst 33342 dan Rhodamine 123. ‘Profiler 
array’ protiom apoptosis manusia digunakan untuk mengenalpasti sasaran 
protin yang bertanggungjawab bagi induksi apoptosis. Tambahan lagi, 
kesan antitumor in vitro kalium koetjapat telah dikaji menggunakan asai 
‘titik tergantung’. Tiga dos kalium koetjapat (25, 50, dan 100 mg/kg berat 
badan) telah dikaji dalam model mencit bogel ‘athymic’ untuk mengkaji 
efikasi in vivo anti-tumor kalium koetjapat. Dalam kajian ini pelbagai 
formulasi KA telah disediakan. Kajian pelarutan menunjukkan bahawa 
derivatif KA iaitu, kalium koetjapat, mempunyai pelarutan air lebih baik 
daripada dispersi pepejal KA. Kajian antikanser in vitro menunjukkan 
bahawa kalium koetjapat mempunyai aktiviti sitotoksik lebih baik daripada 
KA dan kompleks dispersi pepejalnya, terhadap titisan sel HCT 116. asai 
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pewarna fluresen menunjukkan bahawa kalium koetjapat mempunyai sifa t 
menginduksi apoptosis. Ia menginduksi kondensasi kromatin dan 
menurunkan potensi membran mitokondria secara kebergantungan dos. 
Tambahan lagi, ia menaikkan tahap kaspas dalam sel -sel HCT 116.  
Keputusan protin apoptosis ‘array’ menunjukkan bahawa kalium koetjapat 
mempengaruhi aktiviti beberapa protin.  Ia menurun-aturkan ekspresi 
beberapa protin anti-apoptotik dan regulator negatif apoptosis termasuk 
Bcl-2, HSP60, HSP90 dan IGF-1 dalam sel-sel HCT 116 dengan penaik-
aturan protin-protin TRAILR-1 dan TRAILR-2, CD40, IGFBP-6, p27, 
kaspas 3 dan kaspas 8. Tambahan lagi, kalium koetjapat menunjukkan 
kesan antimetastatik terhadap sel HCT 116 dalam asai -asai in vitro. 
Keputusan-keputusan ini mungkin disebabkan oleh penurun-aturan laluan-
laluan signal Wnt, Notch, Hypoxia, MAPK/ERC dan MAPK/JNK dalam 
sel-sel HCT 116, bersama dengan penaik-aturan faktor transkripsi untuk 
laluan-laluan putaran sel (pRb-E2F). KKA juga menghalang proses 
angiogenesis in vitro dengan menghalang proses -proses penembusan, 
penghijrahan dan pembentukan dan pembentukan tiub sel -sel endothelium 
. Kajian toksisiti akut menunjukkan bahawa kalium koetjapat mempunyai 
LD50 lebih daripada 2000 mg/kg dalam tikus betina SD. Keputusan kajian 
tumor ‘spheroid’ menunjukkan bahawa kalium koetjapat mempunyai 
kebergantungan dos potensi antitumor dan data ini berkait dengan 
keputusan kajian tumor in vivo. Kalium koetjapat menunjukkan perencatan 
poten pembiakan tumor (68.15%, 82.35% dan 92.76%, pada 25, 50 dan 
100mg/kg, secara berurutan). Keseluruhannya, keputusan kajian ini 
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menunjukkan bahawa kalium koetjapat mempunyai aktiviti anti -kanser 
terhadap kanser kolorektal.  
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EFFECT OF POTASSIUM KOETJAPATE, A DRIVATIVE OF 
KOETJAPIC ACID ISOLATED FROM SANDORICUM KOETJAPE 
MERR.  ON HUMAN COLORECTAL CANCER. 
 
ABSTRACT 
In the present study an attempt was made to enhance the aqueous 
solubility of KA and to study its anti -colon cancer efficacy using in vitro 
and in vivo methods. Potassium salt of KA i.e., potassium koetjapate was 
prepared by semi-synthetic method. Anticancer activities of potassium 
koetjapate were compared with the native compound i.e., KA. MTT cell 
viability assay was used to obtain and compare the IC 50 values of both the 
compounds. Pro-apoptotic effects of potassium koetjapate were assessed 
using caspases (3/7, 8 and 9), Hoechst 33342 and Rhodamine 123 
fluorescent staining assays. Human apoptosis proteome profiler array was 
used to identify the protein targets responsible for the induction of 
apoptosis. Furthermore, in vitro antitumor effects of potassium koetjapate 
were studied using hanging drop assay. Three doses of potassium 
koetjapate (25, 50, and 100 mg/kg body weight) were tested in athymic 
nude mice model to study the in vivo  anti-tumorigenic efficacy of 
potassium koetjapate. In this study, various formulations of KA were 
prepared. Solubility studies revealed that resultant KA derivative i.e. 
potassium koetjapate had better aqueous solubility than the solid 
dispersions of KA. In vitro anticancer studies revealed that potassium 
koetjapate has better cytotoxic activity than KA and its solid dispersion 
complex towards HCT 116 cell line. Fluorescent staining assays showed 
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that potassium koetjapate has apoptosis-inducing nature. It induced 
chromatin condensation and decreased mitochondrial membrane potential 
in a dose-dependent manner. Furthermore, it increased the levels of 
caspases in HCT 116 cells.   The results on apoptosis protein array show 
that potassium koetjapate modulated the activity of multiple proteins.  It 
down-regulates the expression of multiple anti-apoptotic proteins and 
negative regulators of apoptosis including Bcl -2, HSP60, HSP90 and IGF-
1 in HCT 116 cells with concomitant up-regulation of TRAILR-1 and 
TRAILR-2, CD40, IGFBP-6, p27, Caspase 3 and caspase 8 proteins.  
Furthermore, potassium koetjapate showed antimetastatic effect towards 
HCT 116 cells in a series of in vitro assays. These results are probably due 
to down regulation of   Wnt, Notch, Hypoxia, MAPK/ERC and MAPK/JNK 
signalling pathways in HCT 116 cells coupled with the up-regulation of 
transcription factor for cell cycle (pRb-E2F) pathways. Moreover, KKA 
inhibited angiogenesis in vitro  by stopping endothelial cells 
neovascularization,  migration, tube formation and VEGF release. Acute 
toxicity studies reveal that potassium koetjapate has LD50 more than 2000 
mg/kg in female SD rats. Results of spheroid tumor studies show that 
potassium koetjapate has dose-dependent antitumor potential and this data 
correlates with the outcomes of the in vivo tumor studies. Potassium 
koetjapate showed potent inhibition of tumor growth (68.15%,82.35 % and 
92.76% at 25, 50 and 100mg/kg, respectively). Altogether, outcome of 
present study shows that potassium koetjapate has good anti -cancer activity 
towards colorectal cancer.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Cancer 
A major global health issue, cancer is described as unrestrained 
growth of cells leading to the invasion of local tissues and tumor metastasis 
(1). Cancers are categorized by the type of cells from which the tumors 
originate including carcinoma, sarcoma, blastoma, germ cell tumor, 
lymphoma, leukemia and adenoma (benign tumor of glandular origin), 
adenocarcinoma (malignant adenoma). Cancers de rived from epithelial 
cells that include common cancers such as most types of breast, prostate, 
lung and colorectal cancers are subsumed under carcinoma while sarcoma 
cancer types occurring in connective tissues such as fat, bone, nerve, and 
cartilage. Conditions such as leukemia and lymphoma start off from 
hematopoietic whereas germ cell tumors   which are mostly existing in the 
testicle or the ovary result from pluripotent cells. Blastoma cancers 
originate from immature “precursor” cells or embryonic tissue (2). In 2008, 
lung, breast and colorectal cancers were reported to be the three most 
commonly diagnosed cancers, while in case of cancer -associated 
mortalities worldwide, lung, stomach, and liver cancers were found to be 
the most common cancer types (3) Presently more than 200 kinds of cancer 
have been recognized which are the second major cause of death 
worldwide, overtaken only by heart disease(4). In 2015, cancers of breast, 
colorectal, lung and prostate were estimated to be the most common causes 
of cancer-related mortalities (5).  According a recent report, cancer is now 
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the leading cause of death in 21 states in the USA, cancer is currently the 
primary cause of death, due to exceptionally large reductions in deaths 
from heart diseases. Although cancer-related death rate has decreased by 
23% since 1991, or more than 1.7 mill ion deaths were prevented up to 2012, 
death rates are increasing for cancers of the pancreas, liver, and uterine 
corpus . In developing countries, there are more new cases than what is 
documented in the developed countries (5,600,000 vs. 7,100,000 cases 
respectively(6) . Cancer was found to be the third most common reason for 
deaths overtaken by cardiovascular and septicaemia diseases in Malaysia 
according to the Malaysian National Cancer Registry report in 2007. 
According to another report, three most commonly diagnosed cancers in 
Malaysia were breast, cervical and colorectal cancers followed by bone 
marrow, lung, lymph node and liver cancers respectively while five most 
commonly diagnosed cancers in the male population were lung, colorectal, 
nasopharynx, prostate and lymphoma respectively. Whereas in the female 
population, cancers of breast, colorectal, cervix, ovary and lung were at 
the top list (7). A range of factors may result in an increase in the risk of 
cancer. The causative factors involved in the progress of cancer include 
smoking, obesity, exposure to chemicals, oxidative stress, and radiation as 
external factors while inherited mutations (hyper-activation of oncogenes, 
and inhibition of tumor-suppressing genes), metabolic deregulations, 
hormone imbalance, and dysfunction of immune system are considered as 
the main internal factors(8) . Surgery, chemotherapy and radiotherapy are 
the most common treatments of cancer nowadays (9).   
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1.1.1 Colorectal carcinoma  
Among various types of cancer, colorectal cancer (CRC), a 
malignant tumor of large intest ine, ranks third in the world as a lethal and 
metastatic carcinoma while the incidence and death rates of CRC has 
decreased by around 3% per year in both men and women from 2003 up to 
the end of 2012(5). Still, CRC is a significant cause of mortality in both 
men and women worldwide. According to a survey, every year more than 
945 000 people develop colon cancer out of which around 492 000 patients 
die (10). in the Malaysian Peninsula, CRC is the most prevalent type of 
cancer in men and the third most common cancer in women According to 
the National Cancer Registry Report 2003-2005. The Age-Standardized 
Rate (ASR) was highest among Chinese men, in whom it was more than 
two times that of Indian and Malay men. Chinese women also had an ASR, 
which was more than twice that of Indian and Malay women. Hypertension, 
obesity, abnormal blood lipids, and high fasting blood glucose are 
considered as main metabolic risk factors for colorectal cancer (11) . The 
growth in colorectal tumor is due to the mutational activation of oncogenes 
coupled with the mutational inactivation of tumor suppressor genes . Hence, 
it is described as a multi-step disease that converts normal epithelial cells 
of the colon into invasive carcinoma (Figure 1.1). An ordered series of 
events, recognized as the “Adenoma -Carcinoma Sequence”, causes the 
development of colorectal neoplasms. There must be at least four mutated 
genes to form malignant tumors affected by few further chan ges leading to 
benign tumorigenesis. The histopathologic changes occur due to genetic as 
well as environmental factors. The most important environmental factors 
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include pathogen invasion, toxins, generation of ROS (Reactive Oxygen 
Species) and stress conditions. Currently, the inherited and somatic genetic 
deficiencies contributing to the development of colorectal carcinogenesis 
have been discovered such as sustainable  changes in 
COX2  (Cyclooxygenase-2), KRas, Ctnn-Beta  (Catenin-Beta), APC 
(AdenomatousPolyposisColi),SMAD4 (Smaand MAD (MothersAgainstDe
capentaplegic), p53, TGF-BetaR2 (Transforming Growth Factor-Beta 
Receptor-Type II), BAX (Bcl2 Associated-X Protein), E2F4  (E2F 
Transcription Factor-4) and MMR (Mismatch Repair) genes 
like, MSH2 (MutS Homolog-2), MSH3  (MutS Homolog-3), MSH6  (MutS 
Homolog-6), MLH1  (MutL Homolog-1) and MMP (Matrix 
Metalloproteinase)-1/2/7/9/11/12/14, loss of the 18q21 gene and 
microsatellites instability (12-14). At the beginning, when the normal 
colonic epithelia (Stage-0) is subject to unfavorable conditions such as 
pathogenic invasions, APC and Ctnn-Beta mutations, toxins and generation 
of ROS; it is changed into Dysplastic ACF (Aberrant Crypt Foci) or 
Dysplastic Adenoma or Dysplast ic Epithelia (Stage-I) (15). An increase in 
microsatellite repeat sequences along with KRas and COX2 mutations play 
a major role in transforming Dysplastic epithelia to early adenoma phase 
(Stage-II). KRas mutations occur in 39% of human colorectal cancers such 
as KRas mutations combined with MSH2 (deletion) mutations DCC (point 
mutation in 70% of colon cancers) and MLH1 (substitution, deletion and 
hypermethylation of CpG sites), which lead to the transition fr om early 
adenoma to late adenoma (Stage-III). Lastly, transitions from late adenoma 
to increasingly tumor metastasis through colorectal carcinoma (Stage -IV)) 
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comprise the less frequently targeted genes like BAX via frameshift 
mutations which happen in over 50% of colon adenocarcinomas along with 
deletion in E2F4, MSH3 and MSH6 fallowed by gene modifications of p53 
and TGF-BetaR2, MMP1/MMP2/MMP7/MMP9/MMP11/MMP12 (over-
expression) and SMAD4 mutations (lack of alleles on chromosomes 17 and 
18 in polyploid colorectal tumors). Particularly, point mutation on p53 
gene is the main reason for causing 50% of colorectal cancers whereas 
SMAD4 mutations (aneuploid/polyploid) are linked with metastatic 
carcinoma (16, 17).  
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Figure 1.1: Adenoma-Carcinoma Sequence, Adapted from Qiagen (18)  
 
1.2 Major Signaling Pathways involving in Colon Cancer:  
1.2.1 Wnt/β-catenin Signaling Pathway: 
The Wnt signal transduction pathway is an old pathway that is 
evolutionarily conserved and has a key role in the development of the 
embryo such as cell migration, cell polarity, along with a major role in cell 
to cell signaling (19, 20). Mutations in the Wnt pathway have a fundamental 
7 
role in cancer development, especially in colon cancer. The Wnts consist of 
a large family of nineteen glycoproteins  in humans. So far, major signaling 
branches which are downstream of the Fz receptor have been identified such 
as canonical or Wnt/β-catenin dependent pathway and the non-canonical or 
β-catenin independent pathway. The Planar Cell Polarity and the Wnt/Ca2+  
pathways are two branches of Wnt/β-catenin dependent pathway which are 
being actively dissected at the molecular and biochemical levels (21).  
Around 90% of all colon cancer cases are related to the APC tumor 
suppressor gene mutations, which trigger Wnt/β -catenin accumulation (22). 
β-catenin and TCF/LEF transcription factors combine and consequently 
boost the expression of c-Myc, cyclin D1 and MMP genes involved in 
carcinogenesis and tumor angiogenesis(23) . Therefore, a possible objective 
in curing different types of cancer, i.e. colon cancer, can be the down -
regulation of the Wnt pathway.  
 
1.2.2 Notch Signaling Pathway 
Notch signaling pathway can promote or suppress cell proliferation, 
differentiation, death, and fate specification. This pathway significantly 
interferes in some physiological programs such as apoptosis, adhesion, 
migration and angiogenesis throughout adult tissue renewal leading to the 
development of the organism. Because of its essential role in many 
important processes, abnormal gain or loss of pathway components has 
been directly linked to multiple human diseases including cancer (24, 25). 
Notch can be an oncogene or a tumor suppressor gene based on factors such 
as the timing, cell type, signal strength, and the n ormal function of certain 
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tissues (26) . Various types of cancer including colon, melanoma, renal, 
breast, pancreas, and lung cancers have Notch pathway signaling (27, 28). 
Some studies have shown strong relations between Notch and Wnt 
pathways in colon cancer which strengthen the hypothesis that Notch 
signaling might be in a downstream of Wnt (29-31). Thus, Notch signaling 
pathway can be used in combination with Wnt inhibitors as a potential 
treatment of colorectal carcinoma.  
 
1.2.3  P53 Signaling Pathway 
The P53 is a nuclear protein, which is known as “the guardian of the 
genome” because of its role in the detection of genetic damage and in 
triggering the genetic repair mechanisms(32). It can also trigger apoptosis 
in case of irreparable DNA damage. When P53 is mutated, it will not be 
able to perform its function as frequency (>50%) of mutation in the P53 
gene is the most in human cancer. This indicates that the P53 tumor 
suppressor gene has an a key role in cancer prevention is played by the P53 
tumor suppressor gene through the cell cycle arrest mechanism which may 
result in inducing apoptosis  (33).  Mutations in the P53 suppressor gene 
are common in all cancers, which usually occur in the central DNA-binding 
core domain. Mutations mostly hamper the protein’s ability to attach to its 
target DNA strands, thus preventing transcriptional activation of the genes.  
The P53 protein controls cell death using different mechanisms that result 
in the regulation of genes entangled in both the extrinsic and intrinsic 
pathways of apoptosis either via transcriptional -independent or 
transcriptional-dependent mechanisms (34). Therefore, increasing the 
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amount of P53 could be a promising strategy in the treatment of cancers 
with lower side effects. Recently, small molecules such as small peptides 
have been used to reactivate the suppressed wild -type P53 or to return the 
mutant into a wild-type P53 (35). 
 
1.2.4  Cell Cycle (pRB/ E2F) Signaling Pathway 
Retinoblastoma (Rb) is a malignancy of the developing retina, which 
happens in children and is considered to be the most common malignancy 
of the eye in children (36). The retinoblastoma tumor suppressor (pRB) 
plays an important role in cell cycle processes and apoptosis. The pRB gene 
is mutated in around 50% of all human tumors  . Moreover, genes encoding 
upstream regulators of pRB have been found to be mutated in the remaining 
50% of all human tumors. About 60% of affected individuals have 
unilateral Rb while around 40% have bilateral Rb Heritable retinoblastoma 
is an autosomal dominant vulnerability to Rb RB1 was the first tumor 
suppressor gene cloned. Recently, it has been reported that pRB can bind 
with a series of transcription factors such as E2F and form dimmers tha t 
control the expression of several downstream effector genes involved in 
cell cycle control, mitosis, DNA repair and apoptosis (37). It appears that 
RB1 interacts with more than 100 cell proteins resulting in regulation of 
the critical G1 to S-phase transition in the cell cycle. It has also been found 
that the Rb/E2F complex has the main role in maintaining G1 arrest in 
connection with the p21/p27 family of cdk inhibitors (38).  
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1.2.5  NF-кB Signaling Pathway 
The nuclear factor κB enhancer binding protein (NF -κB) family of 
transcription factors, control the expression of a large group of genes 
engaged in diverse cellular processes including the inflammation, 
immunity, migration, adhesion, cell growth, apoptosis and cell survival. 
Deregulated NF-κB has been linked to a variety of human diseases, 
particularly cancers. The oncogenic role of NF-κB seems to be mediated 
through its anti-apoptotic function, particularly through induction of Bcl -
XL.  The NF- κB family consists of five DNA binding proteins as follows: 
c-Rel, NF- κB 1/p50 NF- κB2/p52, RelA (p65) and RelB, which function 
as various homodimers and heterodimers. A highly conserved 300 -
aminoacid-long N-terminal Rel homology domain (RHD) which is a 
common domain in all five NF- κB proteins functions to dimerization, DNA 
binding, interaction with the inhibitors of NF- κB as well as nuclear 
translocation (39, 40). It was reported in several studies that NF-кB target 
over 200 different genes such as Myc, Rel, and Cyclin D1-4 which are 
engaged in cell cycle regulation, Bcl -2, Bcl-Xl, A1/Bf-1 which function in 
the apoptosis process, VEGF gene which has a critical role in angiogenesis 
process leading to the belief in the oncogenic potential of “normal” NF -kB 
(39, 41, 42). It was also found that NF-kB signaling system has an 
important role in bridging inflammation and cancer (39). Some new studies 
reported on the identification of cancer-associated mutations in upstream 
components of the IkB kinase -NF-kB (IKK-NF-kB) signaling system that 
can result in cell autonomous activation of NF-kB in multiple myeloma 
(43, 44) . Recently, Kojima and his group have reported that LPS increases 
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COX-2 expression in a certain colon carcinoma cell line through NF -kB 
which is continuously activated in colorectal carcinoma tissue samples. 
They also demonstrated that NF-kB is constitutively activated in colorectal 
carcinoma tissues by using an electrophoretic mobility shift assay (EMSA) 
andimmuno-histochemical staining. In addition, they found that NF-kB 
activation is closely related to cancer progression(45) . New recent studies 
suggest that activation of NF-κB appears to perform an essential role in 
cancer development as it was reported that NF-κB is obviously activated 
in 50% of CRC patients and those with colitis  associated tumors and later 
it has been established by mouse model studies that NF-κB functions 
criticality in the development of Colitis -associated cancer (CAC) (40). 
Recently researchers tried to synthesize compounds that target this 
pathway such as cinnamaldehyde which was reported as an apoptosis 
inducer agent acting via mitochondrial pathway, and hence it has been 
found as a potent NF-кB pathway inhibitor. The essential roles taken by 
this pathway in apoptosis inhibition and tumor maintenance suggest that 
inhibitors of the pathway would be effective anti -cancer agents(45-47)  
 
1.2.6  Myc/Max Signaling Pathway 
Numerous studies demonstrated that a mutated version of Myc, 
which is constitutively expressed, leads to the unregulated expression of 
many genes, which result in diverse cancers. Myc has been reported to be 
hyper-activated in 70% of all human cancer cases including colon, breast 
and lung cancers while it acts as an angiogenesis switch as well (48, 49). 
On the other hand, Myc/Max heterodimers induce intracellular transduction 
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pathways which are critical for induction of apoptosis (49) . It has been 
found that Myc is activated via various mitogenic signals such as 
MAPK/ERK pathway(50). A notable tumor shrinking in transgenic mice 
was achieved by suppressing of the Myc/Max which resulted in targeting 
this pathway(51). Another study demonstrated that c-Myc maintains  
embryonal rhabdomyosarcoma (ERMS) transformed phenotype and radio -
resistance by safeguarding cancer cells from radiation-induced apoptosis 
and DNA damage, while stimulating DNA repair induced by radiation. The 
findings suggest that c-Myc targeting can be an effective treatment in 
cancer therapy (48). 
 
1.2.7  Hypoxia pathway  
Aerobic energy metabolism processes such as oxidative 
phosphorylation needs oxygen in eukaryotic cell while low oxygen 
environments activate the hypoxia signaling pathways. Hypoxia signaling 
dysfunction normally happens in conditions such as tumor angiogenesis 
and chronic inflammation. Solid tumors frequently consist of hypoxic 
regions. The cells in the core of tumor which is located too far away from 
blood vessels become hypoxic. Being related to higher invasion risk and 
metastasis, intratumoral hypoxia is more robust to chemotherapy and 
radiation resulted in more patient mortality (52). As a transcription factor, 
hypoxia inducible factor (HIF) causes most of the response in hypoxia 
pathways. HIF-1 complex is a heterodimers protein comprising of an 
exclusive subunit that is tightly expressed (HIF-1α) having 3 isoforms of 
HIF-1α, HIF-2α, and HIF-3α and a regular constitutively-expressed beta 
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subunit (HIF-1β). The presence of oxygen provokes prolylhydroxylases to 
hydroxylate HIF, resulting in the polyubiquitination and degradation of 
HIF while under low oxygen conditions, prolylhydroxylase inhibition leads 
HIF to accumulate which in its turn activates transcription of about 100 
genes encoding proteins that mediate some major biological processes such 
as angiogenesis, wound healing, invasion and metastasis, human 
metabolism, chondrocyte survival in bone growth plates, autophagy and 
cell death. Increased HIF-1α or HIF-2α levels are found in human colon, 
breast, prostate and lung carcinomas, and are linked with increased patient 
mortality. Some experimental data shows that hampering HIF-1 signaling 
blocks tumor growth in mouse models(53, 54). Research has indicated that 
in normal oxygen pressure, NF-κB (nuclear factor κB) directly modulates 
HIF-1α expression. Investigation of siRNA (sma ll interfering RNA) as for 
individual NF-κB members displayed differential effects on HIF -1α mRNA 
levels, implying that NF-κB can control expression of normal HIF -1α 
VEGF-A and Ang-2 genes which are associated with extreme tumor 
angiogenesis and metastasis(52, 54). Another study has shown that HIF-1α 
and its downstream target miR-210 is provoked by hypoxia blocking Bcl-2 
expression and increasing autophagy, hence this triggers resistance to 
radiotherapy in colon cancer cells. (55). The critical role of HIF in 
regulating the expression of multiple genes involved in tumor metabolism 
and angiogenesis makes it a potential target in cancer therapy. Hence, 
greater anticancer effects may be achieved by obstruction of HIF -1. 
Therefore, HIF inhibitors including the Klugine, Betulonic acid, phenethyl 
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isothiocyanate, taxol, and Acriflavine are still investigated for their anti -
cancer properties (53, 56). 
 
1.2.8  MAPK Signaling Pathways  
MAPK pathway is a term used for referring to a three kinases module 
activated by phosphorylating one another sequentially as a reaction to 
different types of stimuli including neurotransmitters, cellular stress, 
cytokines, growth factors  and cell adherencestimuli including 
neurotransmitters, cellular stress, cytokines, growth factors  and cell 
adherence(57). This pathway uses one of the most generic singling designs 
discovered in biological signal transductions. Mitogen -activated protein 
kinases (MAPKs) are serine/threonine-specific protein kinases that were 
broadly used during evolution in many physiological processes such as 
gene expression, mitosis, growth control, cellular adaptation to chemical, 
physical stress, metabolism, motility, cell differentiation and survival, 
inflammation and apoptosis in all eukaryotic cells. There are 14 MAPKs in 
mammals, which have been divided into seven groups. Conventional 
MAPKs consist of the extracellular signal regulated kinases 1/2 (ERK1/2), 
p38 isoforms (α, β, γ, and δ), c-Jun amino (N)-terminal kinases1/2/3 
(JNK1/2/3), and ERK5(58) . The MAPK/JNKs and MAPK/ERKs are 
involved in growth factor signaling, regulation of mitosis, migration and 
apoptosis while MAPK/p38 play  an important role in inflammation (59). It 
was found that de-regulation of the above pathway resulted in various 
diseases such as cancer, immunological disorders, degenerative and 
inflammatory syndromes. As reported, MAPKs down regulate over 170 
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tumor suppressor genes including Tob1, JunD and Ddit3, which suppress 
cell growth and proliferation (60). Phosphorylation activates the MAPK 
pathway through a MAPKK/MKK (MAPK kinase), and that is 
phosphorylated by a MAPKKK/MKKK (MAPKK kinase). It was also found 
that MAPKs are disabled by several phosphatases including a preserved 
family of phosphatases named MAP kinase phosphatases (MKPs). These 
types of enzymes can hydrolyze the phosphate from phosphotyrosine and 
the phosphothreonine remains. The deletion of each phosphate group 
extremely reduces MAPK activity essentially giving up signaling. It has 
been found that some types of tyrosine phosphatases take part in 
inactivating MAP kinases including phosphatases such as STEP, HePTP, 
and PTPRR in mammals (61, 62).  
Most inducers of the MAPK pathway begin signaling via activating 
receptors in the cell membrane, which result in activation of MAPKKK 
typical through a small GTPase. There is a large number of known MAPK 
agents including mostly of protein kinases, transcription factors, and 
cytoskeletal proteins. When MAPK is activated it can transfer from the  
cytoplasm to the nucleus, in which it controls gene transcription via 
impacting the structure of chromatin and transforming transcription factors 
activity (57, 62). It was reported that the activation of MAPK/ERK pathway 
provoked cell cycle arrest and apoptosis and hence could be an effective 
therapeutic target of different types of cancer such as osteosarcoma and 
pancreatic cancer therefore serious attempts were made to produce 
inhibitors of the ERK and JNK pathways and examine them in clinical trials 
(58, 63). 
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1.3  Apoptosis 
The apoptosis process was first described in 1972 as a distinct form 
of cell death in term of morphology, whereas some characteristics of this 
phenomenon were explained earlier (64). So far apoptosis has been 
accepted as the most important type of genetically determined or 
“programmed” death of cells that is involved in cell disposal. Nevertheless, 
there are other types of programmed cell death which are also defined or 
will be discovered in the future (65, 66). Generally, organisms having 
multi-cells use two major methods for cell disposal: necrosis and apoptosis.  
Necrosis can be caused due to the breaking apart of the plasmatic 
membrane as a result of the formation of a swelling process. In contrast, in 
apoptosis, chromatin is condensed followed by fragmentation and forming 
apoptotic remains quickly engulfed by the macrophages hence this process 
does not induce any inflammatory reaction (67). Apoptosis can be activated 
by a variety of stimuli such as changes in the concentration of growth  
factors, ionizing radiations, heat shock and other cellular stress, infection 
by bacterial or viral particles, genetic mutations and damage of DNA (64, 
67). Generally, cleavage of proteins, caspase cascade activation, changes 
in cellular bioenergetics and membrane potential along with expression of 
cell surface proteins which cause the early detection of apoptotic cells 
followed by DNA fragmentation are considered as the main features of 
apoptosis. Mitochondria perform a main role in mediating apoptosis by 
releasing pro-apoptotic proteins such as cytochrome c, Smac, Omi and AIF 
into the cytosol. Excessive apoptosis can result in the progress of acquired 
immune deficiency syndrome (AIDS), renal damage, neurodegenerative 
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disorders and cardiac ischemia. On the other hand, reduced ap optosis can 
result in development of cancer and autoimmune diseases (68, 69) . 
 
1.3.1  Apoptotic Pathways 
Apoptosis may be caused in mammals through three pathways based 
on apoptosis regulators and the location where they act: the first pathway 
is extrinsic pathway, started by the ligation of death receptors before the 
activation of caspase-8 and processing extracellular death-inducing; the 
second pathway is called intrinsic pathway, started by cell stress before the 
activation of caspase-9, and the third type of pathway is called 
Granzyme/Perforin pathway, which can trigger members of the caspase 
family by processing of caspase zymogens. Nevertheless, granzyme A 
functions in a caspase-independent way. Ultimately, the apoptosis 
pathways lead to the execution pathway ending in cytomorphological 
features of apoptosis suc cell h as chromatin condensation, shrinka ge, 
cytoplasmic blebs formation prior to phagocytosing the apoptotic bodies 
(64). A summarized schematic image of apoptosis pathways is illustrated 
in Figure 1.2. 
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Figure 1.2: Schematic illustration of apoptosis. The three pathways of 
apoptosis i.e. extrinsic, intrinsic and perforin/granzyme pathways. 
Adopted from (64). 
 
 
1.3.1(a) Extrinsic Apoptotic Pathway 
The extrinsic pathway or death receptor-mediated pathway is 
triggered by binding of extra- cellular ligands with a family of tumor 
necrosis factor death receptors which are located in the cell membrane. Fas 
(fibroblast associated antigen) and tumour necrosis factor receptor (TNF - 
R) are considered as typical death receptors which are involved in this 
pathway. These receptors contain an extracellular cysteine -rich site in 
order to bind the ligand, and an intracellular site for signal conduction. 
FasL/FasR, TNF-alpha/TNFR1, Apo2L/DR4/DR5 and Apo3L/DR3 are 
considered as the most prominent ligands and their corresponding receptors 
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of this pathway. Binding of Fas ligand to FADD (Fas-associating protein 
with death domain) and the binding of TNF ligand to TNF receptor lead to 
the binding of the adapter protein TRADD with complex of FADD and 
RIP(64, 70) . Subsequently FADD binds to procaspase-8 through 
dimerization of the death effector domain leading to formation of death -
inducing signaling complex (DISC). Next, DISC activates downstream 
caspases 3 or other executioner caspases resulting in destruction of cellular 
targets and apoptosis. Moreover, in certain cell types, BH3 -only protein 
(Bid) is activated by caspase-8 resulting in truncated Bid (tBid). 
Subsequently, tBid moves to the mitochondria and activates cytochrome c 
release leading to activation of caspase-9 and caspase-3(67). The whole 
process is described in Figure 1.3.  
 
1.3.1(b) The Intrinsic Pathway of Apoptosis  
The intrinsic pathway of apoptosis is initiated via non-receptor 
mediated mitochondrial-stimuli that act directly on targets inside the cell 
by producing intracellular signals which can be either positive or negative. 
The lack of certain growth factors, cytokines and hormones create negative 
signals followed by prevention of apoptosis. On the contrary, loss of 
apoptotic suppression leads to activation of apoptosis via positive signals 
such as radiation, oxidative stress, hypoxia, viral infections, and toxi ns 
which result in Bax/Bak insertion into mitochondrial membrane. The 
change in mitochondrial transmembrane by Bax/Bak is followed by loss of 
the mitochondrial transmembrane potential and releasing of pro -apoptotic 
proteins such as Cytochrome c into the cytosol from the intermembrane 
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space(64, 71) .  Moreover, BH3-only proteins, such as Bid and Bim are 
involved in homo-oligomerisation of Bax or Bak which induce their pro -
apoptotic function. Subsequently, Cytochrome c binds to the Apaf1 and 
(d)ATP causing the connection of pro-caspase-9 to the complex and 
forming the Apoptosome. Activated caspase-9 in turn induces caspase-3 
and triggers proteolytic cascade. In contrast, anti -apoptotic Bcl-2 family 
members, for example Bcl-2 and Bcl-XL, inhibit cytochrome c release, 
probably via inhibition of Bax and Bak. Furthermore, mitochondria release 
many other polypeptides such as AIF, endonuclease G, second 
mitochondrial activator of caspases (Smac/Diablo) which can promote 
caspase activation via suppressing the inhibitory effects of anti -apoptosis 
proteins (IAPs) while AIF and Endo G create DNA damage and 
condensation(67, 72). In case of apoptosis initiation via chemotherapeutic 
agents, the mitochondrial pathway is more important than the death -
receptor pathway for example caspase 9–deficient cells and Apaf-1–
negative thymocytes are resistant to chemotherapeutic agents, however 
they can be stimulated into apoptosis via  Fas, TRAIL, or TNF (73). 
 
1.3.1(c) Perforin/granzyme Pathway  
Granzyme B (Gzm B) is a caspase-like serine protease that is 
released by cytotoxic T lymphocytes (CTL) and natural ki ller (NK) cells 
to kill virus-infected and tumor cells. Therefore, granzyme B plays a 
significant role in human pathologies such as anti -viral immunity and 
tumor immune surveillance. The serine proteases granzyme A and 
granzyme B are the most important component within the granules which 
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have been examined in recent years (64, 74). Although caspase 3 was the 
first substrate to be identified for Gzm B, other reports have shown that 
Gzm B can stimulate several members of the caspase family of cysteine 
proteases by proteolytic processing of their substrates (75) . Gzm B is able 
to cleave proteins at critical aspartate residues, thereby stimulating pro -
caspase-10 which cleaves ICAD (Inhibitor of Caspase Activated DNAse). 
Additionally, Gzm B uses the mitochondrial pathway to improve the death 
signal through specific cleavage of Bid where this protein stimulates the 
release of mitochondrial cytochrome c into the cytosol (76, 77) . Goping 
and her colleagues also have shown that Gzm B can directly stimulate 
caspase-3 resulting in the release of pro-apoptotic proteins that suppress 
caspase inhibition and direct induction of the execution phase of ap optosis 
which suggest that both the mitochondrial pathway and direct stimulation 
of caspase-3 are essential for granzyme B-induced killing (75). Other 
research indicates that death receptors and caspases do not play any role in 
the apoptosis of activated T helper 2 cells induced by T cell receptors 
because obstructing their ligands does not have any effect on apoptosis. In 
contrast, adapter proteins with death domains, Fas -Fas ligand interaction, 
and caspases are involved in apoptosis and regulating cytotoxic T helper 1 
cells whereas granzyme B does not have any impact. Also granzyme A has 
a major role in cytotoxic apoptosis induced by T cells and stimulation of 
pathways that are independent from caspases. Granzyme A causes DNA 
disintegration using DNAse NM23-H1. The nucleosome assemblage 
protein SET inhibits the NM23-H1 gene. Granzyme A protease cuts the 
SET complex and, therefore prevents the inhibition of NM23-H1, causing 
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apoptosis via degradation of DNA;; hence inactivation of this complex by 
granzyme A probably results in apoptosis through hindering the DNA 
maintenance and chromatin structure stability (64, 78). 
 
 
Figure 1.3:  TRAIL death-receptor pathway of apoptosis.  
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1.3.1(d) Execution Pathway 
Execution Pathway is considered the final pathway of apoptosis as 
the extrinsic and intrinsic pathways both terminate at the execution phase. 
Caspase-3, caspase-6, and caspase-7 function as effector or “executioner” 
caspases, cleaving various substrates such as  cytokeratins, PARP, the 
nuclear protein NuMA and the plasma membrane cytoskeletal protein alpha 
fodrin resulted in degradation of nuclear material and cytoskeletal proteins 
that are followed by the major morphological and biochemical changes in 
apoptotic cells(79).  Execution caspases activation in the signaling cascade 
is the apoptotic commitment point in which the cell kills itself (80) . 
Caspase-3, as the main executioner caspase, is activated by any of the 
initiator caspases (caspase-8, caspase-9, or caspase-10). Subsequently 
caspase-3 cleaves ICAD (endonuclease CAD mixed with its inhibitor) to 
release CAD which causes degradation of chromosomal DNA followed by 
chromatin condensation. Moreover, caspase-3 causes cytoskeleton 
rearrangement followed by disintegration of cells and formation of 
apoptotic bodies(64). Screening the translation yields of small 
complementary DNA pools recognized that gelsolin was a vital substrate 
for caspase-3 while in Fas-activated cells it was cleaved in vivo in a 
caspase-dependent manner. Caspase-3 cleaves gelsolin and its fragments 
which cause cleavage of actin filaments in a calcium independent way. 
Additionally, expression of the gelsolin cleavage yield in multiple cells 
resulted in cell contraction and separation from the plate before 
fragmentation of DNA and apoptosis induction, therefore cleaved gelsolin 
is considered as an important physiological effector of morphologic change 
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during apoptosis (81) . Endonuclease-mediated DNA fragmentation and 
apoptotic body formation are the final  characteristic morphological 
features of apoptosis. The findings show that the presence of 
phosphotidylserine on the outer membrane leaflet, surface of apoptotic 
cells, permits their early uptake and disposal with no release of cellular 
constituents resulting in no inflammatory response (82). 
 
1.3.2  Caspase Family 
Caspases are intracellular proteases which are involved in 
programmed cell death, inflammation, cell proliferation, survival and 
differentiation. Activation of caspases is generated by a spec ific stimulus 
through a conserved mechanism. After activation, caspases perform 
proteolysis of downstream substrates to trigger a cascade of events that are 
terminated in the desired biological response(83). In fact, some caspases 
are vital for apoptosis but some are not required. Although aspartate at P1 
position is generally necessary for all caspase substrates, different caspases 
demonstrate different substrate preferences. Some caspases such as 
caspase-8 and -10 have long pro-domains along with special motif like 
DED while caspase-1, -2, -4, -5, -9, - 11 and -12 use domains (CARD) 
which allow their responses to other proteins leading to signaling 
pathways(67) . Caspases were divided into two simple groups: “apoptotic” 
and “pro-inflammatory”, which was a helpful classification for several 
years. However, most apoptotic members (caspase-2, -3, -6, -7, -8, -9, and 
-10) are attributed to at least one non-apoptotic role. Likewise, “non -
apoptotic” candidates such as caspase -1, -4, and -5 are expected to 
